Pharmacokinetics of recombinant human growth hormone administered by cool.click™ 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle by Brearley, Chris et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Clinical Pharmacology
Open Access Research article
Pharmacokinetics of recombinant human growth hormone 
administered by cool.click™ 2, a new needle-free device, compared 
with subcutaneous administration using a conventional syringe and 
needle
Chris Brearley1, Anthony Priestley2, James Leighton-Scott2 and 
Michel Christen*3
Address: 1Clinical Research, Serono International SA, 1211 Geneva, Swizerland, 2LCG Bioscience, Bourn Hall, Bourn, Cambridge CB3 7TR, UK 
and 3Patients Care Technologies Center of Expertise, Merck Serono International SA, 1211 Geneva, Switzerland
Email: Chris Brearley - chrisbrearley@doctors.org.uk; Anthony Priestley - anthony.priestley@LCG-Bourn.co.uk; James Leighton-
Scott - drJames.Leighton-Scott@napp.co.uk; Michel Christen* - michel.christen@merckserono.net
* Corresponding author    
Abstract
Background: Growth hormone (GH) is used to treat growth hormone deficiency (GHD, adult and paediatric), short
bowel syndrome in patients on a specialized diet, HIV-associated wasting and, in children, growth failure due to a number
of disorders including Turner's syndrome and chronic renal failure, and in children born small for gestational age.
Different brands and generic forms of recombinant human growth hormone (r-hGH) are approved for varying indications
in different countries. New ways of administering GH are required because the use of a needle and syringe or a device
where a patient still has to insert the needle manually into the skin on a daily basis can lead to low adherence and sub-
optimal treatment outcomes. The objective of this study was to assess the relative bioavailability of r-hGH (Saizen®,
Merck Serono) administered by a new needle-free device, cool.click™ 2, and a standard needle and syringe.
Methods: The study was performed with 38 healthy volunteers who underwent pituitary somatotrope cell down-
regulation using somatostatin, according to a randomized, two-period, two-sequence crossover design. Following
subcutaneous administration of r-hGH using cool.click™ 2 or needle and syringe, pharmacokinetic parameters were
analysed by non-compartmental methods. Bioequivalence was assessed based on log-transformed AUC and Cmax values.
Results: The 90% confidence intervals for test/reference mean ratio of the plasma pharmacokinetic variables Cmax and
AUC0-inf were 103.7–118.3 and 97.1–110.0, respectively, which is within the accepted bioequivalence range of 80–125%.
r-hGH administered by cool.click™ 2 is, therefore, bioequivalent to administration by needle and syringe with respect
to the rate and extent of GH exposure. Treatment using cool.click™ 2 was found to be well tolerated. With cool.click™
2 the tmax was less (3.0 hours) than for needle and syringe delivery (4.5 hours), p = 0.002 (Friedman test), although this
is unlikely to have any clinical implications.
Conclusion: These results demonstrate that cool.click™ 2 delivers subcutaneous r-hGH exposure that is bioequivalent
to the conventional mode of injection. The new device has the additional advantage of being needle-free, and should help
to increase patient adherence and achieve good therapeutic outcomes from r-hGH treatment.
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Background
Growth hormone deficiency (GHD) affects both children
and adults, and clinical manifestations vary depending on
the age of onset [1]. Children present with short stature
and low growth rate [2], while adults have altered body
composition and metabolism with reduced physical per-
formance [3]. At all ages, quality of life is impaired [4,5].
For many years, replacement therapy using exogenous
human growth hormone (GH) has been used successfully
to treat children with GHD [6], and has more recently
benefited adult patients with GHD [7]. GH is now pro-
duced using recombinant DNA technology [8], and is also
used to treat growth failure due to a number of other dis-
orders including Turner's syndrome [9-11] and chronic
renal failure [12], and in children born small for gesta-
tional age [13].
Conventional GH therapy for GHD was originally devel-
oped as a daily subcutaneous injection using a standard
needle and syringe. However, many patients (a large pro-
portion of who are children and adolescents) find that
using needles is painful and this provokes fear of the injec-
tion procedure, resulting in potential non-adherence and
sub-optimal therapy. Efforts have focused on finding
alternative means of administering GH to patients. Deliv-
ery devices such as pre-filled syringes, manual injector
pens, auto-injectors, injectors with hidden needles and
needle-free devices have been introduced in an attempt to
improve dosing accuracy and flexibility, ease-of-use, con-
venience, adherence and patient-friendliness [14-19].
However, the majority of injections still require manual
insertion of the needle into the skin by the patient.
Needle-free devices have been introduced for GH therapy,
having already been used for some time to administer
insulin to patients with diabetes mellitus [20] although,
in the latter case, local reactions may have limited more
widespread acceptance. These devices expel the liquid
preparation of the hormone through a small disposable
nozzle at high pressure so that it is forced through the skin
and dispersed in the subcutaneous region. This mode of
administration is as effective as a conventional injection
[21,22], but has the added advantage of reduced adverse
psychological effects [23].
One of the available needle-free devices is the cool.click™
(cool.click® in the USA), a commercially available device
customized and introduced by Serono in 2000 for the
purpose of injecting recombinant human growth hor-
mone (r-hGH) with variable dosing and child-friendly
ergonomic features [24]. The delivery of r-hGH by
cool.click™ is bioequivalent to needle injection of r-hGH
[22]. It has been shown that patients using needles and
syringes to inject r-hGH had lower adherence (more
patients missed over half of their prescribed dose) than
those using cool.click™, resulting in significantly reduced
growth rates than those who missed fewer doses [25].
Some adults and teenagers have indicated a preference for
this needle-free injection device, and young children over-
all favoured it [22,23], reporting that cool.click™ delivery
creates less discomfort than traditional needles.
In response to feedback regarding a wish for simplifica-
tion of dose selection and improvement of the ergonom-
ics of the present device, the next-generation cool.click™ 2
needle-free injection device for administration of r-hGH
has now been developed by Merck Serono (an affiliate of
Merck KGaA, Darmstadt, Germany). The new device is
similar to the current version of cool.click™, with the addi-
tional benefit that it allows dosing in milligrams. The orig-
inal cool.click™ device allowed dosing only by volume,
which meant clinicians had to convert from mass (milli-
grams r-hGH prescribed) to volume (millilitres of solu-
tion to be injected), a procedure that could be further
complicated by the fact that different volumes of solvent
could be used during reconstitution of the Saizen® powder
for injection. In addition, the reading of the cool.click™
linear analogue dosing scale could be difficult – a vertical
scale had to be aligned with a horizontal scale to set the
required injection volume. In cool.click™ 2, this analogue
scale has been replaced by a digital LCD dose readout.
Lastly, compared with the original device, cool.click™ 2 is
quieter in operation and has a modified design for ease of
use and to facilitate handling by children (with smaller
hands).
The main objective of this study (Study No. 25821) was to
demonstrate that r-hGH administration using the
cool.click™ 2 needle-free delivery device was bioequiva-
lent to injection with a standard syringe and needle, the
reference standard mode of injection.
Methods
Subjects
Healthy male volunteers with pituitary somatotrope cell
down-regulation were screened for eligibility, for recruit-
ment into the study. To be eligible for inclusion, subjects
were required to fulfil the following criteria: age 21–50
years; have a body weight greater than 60 kg and a body
mass index (BMI) in the range of 22–30 kg/m2; have vital
signs in the normal range; and must have agreed to use
barrier contraception during the study and for 3 months
following completion of the post-study visit. A subject
was not entered into the study if he had evidence of any
surgical or medical condition that might have interfered
with the pharmacokinetics of the investigational medici-
nal product or if he had received any investigational drug
in the 12 weeks prior to dosing.BMC Clinical Pharmacology 2007, 7:10 http://www.biomedcentral.com/1472-6904/7/10
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Study design
The study was designed as a phase I, randomized, open-
label, two-period, two-sequence crossover study. Treat-
ment started within 21 days of screening. Each study
period lasted 3 days, with a washout period of at least 7
days between drug administrations. The subjects were ran-
domly assigned to one of two treatment sequences. Sub-
jects were allocated a randomization number in
sequential, chronological order immediately prior to first
dose administration, in accordance with the randomiza-
tion list supplied by the sponsor (Serono).
The first treatment sequence received a 0.5 mL (2.92 mg)
subcutaneous dose of r-hGH (Saizen®, Merck Serono)
administered by standard needle and syringe (period 1)
followed by administration of the same dose of rhGH
using the cool.click™ 2 needle-free injection device
(period 2). The second treatment sequence received 0.5
mL (2.92 mg) r-hGH administered by the cool.click™ 2
device (period 1) followed by administration of the same
dose of r-hGH using a standard needle and syringe
(period 2).
The protocol was approved by the local research ethics
committee and conducted in accordance with the Decla-
ration of Helsinki and good clinical practice. Subjects gave
written informed consent to participate in the study.
Experimental procedures
The subjects remained in the clinical unit from 16 hours
before dosing until 30 hours post-dose. To down-regulate
endogenous GH sufficiently to enable accurate assess-
ment of serum GH concentration-time profiles, somato-
statin (3 mg) was given intravenously by continuous
infusion for 25 hours (corresponding to a rate of approx-
imately 1.75 μg/kg body weight/hour), commencing 1
hour prior to dosing with r-hGH to allow pituitary soma-
totrope cell down-regulation to be established.
Subcutaneous injections of GH were administered alter-
nately to the left or right lower external abdominal wall
with the subject in a relaxed sitting position. A different
location on the external abdominal wall was used for the
cool.click™ 2 needle-free injection device. The abdominal
wall below the umbilicus was divided into two areas; one
injection was to be administered in each area. The second
injection had to be administered at least 10 cm from the
first one. Each injection site was clearly circled with a per-
manent marker prior to dosing.
The 0.5 mL (2.92 mg) dose of r-hGH administered yielded
serum hGH concentrations that remained above the limit
of quantification of the hGH assay (Euro/DPC Ltd., UK;
lower limit of quantification = 3.1 mIU/L) for a sufficient
period to enable accurate assessment of the serum hGH
concentration-time profile. Blood samples for determina-
tion of PK serum hGH concentrations were taken imme-
diately prior to dosing and at 1, 2, 3, 4, 4.5, 5, 5.5, 6, 7, 8,
10, 12, 18 and 24 hours post-dosing in both treatment
periods.
Safety data
All clinical laboratory data outside the normal range were
identified. Subject parameters including demographics
and baseline characteristics, vital signs and clinical labora-
tory blood parameters were tabulated and assessed by
descriptive statistical analyses.
The post-study examination was performed at the end of
the study period 14 ± 3 days after the last dosing. Descrip-
tive summaries were recorded for selected parameters
(including demographics and baseline characteristics)
using summary statistics [n, mean, standard deviation
(SD), median, minimum, maximum] and frequency dis-
tributions (n, %).
Close monitoring of adverse events (AEs) was conducted
throughout the study, and AEs were recorded but were not
statistically evaluated. Local tolerability was assessed by
inspection of the injection site at pre-scheduled time
points at each period for any local reaction (redness,
swelling, induration or bruising) and the severity of the
reactions was evaluated.
Data management and analysis methods
Serum concentrations of GH were analysed for each sub-
ject by non-compartmental methods using WinNonLin®
Professional 4.1 (Pharsight, USA).
The following pharmacokinetic parameters were com-
puted: area under the serum concentration-time curve
from time zero to the last quantifiable concentration
(AUC0-last); area under the serum concentration-time
curve extrapolated to infinity (AUC0-inf); peak serum con-
centration (Cmax); time of peak serum concentration
(tmax); and elimination half-life (t1/2).
The areas under the GH concentration-time curves were
calculated according to the log-linear trapezoidal rule
[26].
Bioequivalence was assessed according to EU Guideline
CPMP/EWP/QWP/1401/98 and the FDA Code of Federal
Regulations. Following logarithmic transformation, an
analysis of variance (ANOVA, SAS®) was performed on
GH metrics (Cmax, AUC0-last, AUC0-inf and tmax) of the full
analysis population. There were no imputations for miss-
ing data. The ANOVA model consisted of the logarithmi-
cally transformed Cmax parameter as the response variable
with factors for sequence, subject nested in sequence,BMC Clinical Pharmacology 2007, 7:10 http://www.biomedcentral.com/1472-6904/7/10
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period and mode of administration (treatment). Using an
average bioequivalence approach, a 90% confidence
interval (CI) for the true ratio test (needle-free device) to
reference (needle injection) of the means of the two treat-
ments was produced from this model and compared with
the equivalence acceptance limits 80–125%.
Based on data from previous Serono r-hGH studies, when
the sample size in each sequence group is 15 (and the
total sample size is 30), a crossover design has a 90%
power to demonstrate equivalence within the acceptance
limits of 80–125%, assuming that the expected ratio of
means was 1.000, the crossover ANOVA, MSE (ln scale)
was 0.250 [the SD differences, σd (ln scale) were 0.354],
that data were analysed in the natural log scale using t-
tests for differences in means, and that each t-test was
made at the 5% level. Taking into account a potential
drop-out rate of approximately 20%, it was estimated that
approximately 38 subjects were required to complete this
study.
The pharmacokinetic analysis population consisted of all
38 subjects (100%) who were randomized into this study
and who had evaluable pharmacokinetic data for both
periods.
The analysis of the parameter tmax was conducted using
the non-parametric Friedman test using untransformed
tmax data.
Results
Thirty-eight healthy male volunteers completed the study.
Demographic and baseline characteristics for each subject
(Table 1) were in compliance with specific inclusion and
exclusion criteria. There were no major protocol devia-
tions, no subjects dropped out and no subjects were with-
drawn.
The ANOVA model assumptions were met satisfactorily
and there was no significant sequence effect (p = 0.980).
The mean ± SD serum concentration vs time profiles for
GH following administration of 2.92 mg of r-hGH by
either the needle-free device, cool.click™ 2, or by needle
injection were generally similar throughout the 25-hour
blood-monitoring period (Figure 1). Geometric mean val-
ues for AUC0-inf, AUC0-last and t1/2 were similar between
the two administration methods (Table 2). The maximum
serum GH concentrations (Cmax) of 18–20 ng/mL were
observed 3–4.5 hours (tmax) after drug administration
(Table 2, Figure 1).
The 90% CIs for the ratio of test (new cool.click™ 2 device)
to reference (standard syringe with needle) expressed as a
percentage for AUC0-last  (98.1, 112.0), AUC0-inf  (97.1,
110.0) and Cmax (103.7, 118.3) were all within the speci-
fied acceptance range (80–125%) for average bioequiva-
lence (Table 2).
The median tmax following dosing with the needle and
syringe was 4.5 hours, compared with 3 hours following
dosing using the cool.click™ 2 device (Table 2), and Fried-
man testing showed that this difference was statistically
significant (p = 0.002).
No serious or life-threatening AEs were observed, and no
subject was withdrawn due to AEs. The majority of AEs
were of mild intensity and short duration, most frequently
headache (needle and syringe, n = 11 [20%]; cool.click™
2, n = 9 [13.2%]), and nausea of mild severity (needle and
syringe, n = 10 [18.2%] and cool.click™ 2, n = 12
[17.6%]). Although there was a higher incidence of local
redness in subjects after use of the cool.click™ 2 device
compared with the use of needle and syringe (14 vs 3
affected subjects, respectively), this was generally mild
and was not associated with any significant difference in
pain, bruising, swelling, induration or itching. Redness
after the use of cool.click™ 2 was most prevalent between
the 5 minute and 4 hour assessments, but was experienced
at each of the scheduled assessments. The incidence of
redness was highest at the 5 minute and 4 hour assess-
ments (14 subjects (36.8%) and 9 subjects (23.7%),
respectively). Five subjects experienced pain after dosing
with needle and syringe and 3 experienced pain after dos-
ing with cool.click™ 2.
In this study, statistical assessment of the extent and rate
of absorption of r-hGH shows that administration by a
new needle-free device, cool.click™ 2, is bioequivalent to
standard needle injection and demonstrates similar good
tolerability.
Discussion
The results of this study demonstrate that the concentra-
tion-time profile of hGH following subcutaneous delivery
of r-hGH using the cool.click™ 2 needle-free injection
device is comparable to the concentration-time profile of
the same dose of r-hGH administered subcutaneously by
a needle and syringe. Regulatory guidance stipulates that
the 90% CIs for the ratios (test to reference) of the areas
under the serum concentration vs time curves (AUC ratio)
Table 1: Summary of baseline subject demographic data
Mean SD Range n
Age (years) 35.40 8.31 22.0; 49.0 38
Height (m) 177.80 6.15 160.0; 188.0 38
Weight (kg) 80.67 7.49 66.5; 97.5 38
BMI (kg/m2) 25.50 1.82 22.2; 29.8 38
BMI, body mass index; SD, standard deviationBMC Clinical Pharmacology 2007, 7:10 http://www.biomedcentral.com/1472-6904/7/10
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and the maximum plasma drug concentrations (Cmax
ratio) must fall between 80% and 125% [27], and this
study shows that both the rate and extent of exposure of r-
hGH meet the accepted criteria for bioequivalence. These
criteria have been used for many years, and are the same
for all drugs and routes of administration.
For the purposes of establishing bioequivalence,
cool.click™ 2 was compared with needle and syringe deliv-
ery, which is considered to be the standard reference for
bioequivalence assessment of GH therapies. Its predeces-
sor, cool.click™, was previously proven to be bioequiva-
lent to this reference using similar methods [22], and this
approach has also been used for another jet injection
device [28].
The earlier time to maximum plasma concentration (tmax)
for the cool.click™ 2 device compared with needle and
syringe delivery is unlikely to have any clinical implica-
tions on the chronic dosing regimens used for GH ther-
Mean hGH (± SD) serum concentration vs time profiles following subcutaneous administration of 2.92 mg rhGH/subject using  either the cool.click™ 2 device or standard syringe with needle Figure 1
Mean hGH (± SD) serum concentration vs time profiles following subcutaneous administration of 2.92 mg rhGH/subject using 
either the cool.click™ 2 device or standard syringe with needle.
30
25
20
15
r
-
h
G
H
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
10
5
0
048 1 2
Time (hours)
16 20 24
Cool.click II
Needle and syringe
Table 2: Mean (CV%) pharmacokinetic parameters after subcutaneous administration of 2.92 mg r-hGH/subject by cool.click™ 2 or 
needle injection
cool.click™ 2 
(test) mean (CV%)
Needle and syringe 
(reference) mean (CV%)
Ratio 
(test/ref)
90% CI 
for ratio
Falls within 80–125% 
range?
p-value
AUC0-last (hours·ng/mL) 125.1 (30) 119.3 (27) 104.8 98.1, 112.0 Yes
AUC0-inf (hours·ng/mL) 135.5 (27) 131.1 (24) 103.4 97.1, 110.0 Yes
Cmax (ng/mL) 20.0 (43) 18.0 (37) 110.8 103.7, 
118.3
Yes
tmax (hours)* 3.0 (2–6) 4.5 (2–6) 0.002
t1/2 (hours) 2.17 (42) 2.26 (37)
CV, coefficient of variation; AUC0-last, area under the serum concentration-time profile from time zero to the last quantifiable concentration; AUC0-
inf, area under the serum concentration-time profile from time zero to infinity; Cmax, maximum serum concentration; tmax, time that Cmax occurs; t1/
2, elimination half-life. Means are geometric least square means, n = 38
* Median (range)BMC Clinical Pharmacology 2007, 7:10 http://www.biomedcentral.com/1472-6904/7/10
Page 6 of 7
(page number not for citation purposes)
apy. This is because the r-hGH therapeutic effect is not
directly related to tmax as is often the case with a single-
dose therapy, for example a hypnotic used to induce sleep.
A possible explanation for the difference in tmax might be
the nature of the jet injection, which tends to administer
the drug deeper than by needle and with a wider spread
and, therefore, the hormone is dispersed faster and
absorbed into the blood faster. A similar observation has
also been recorded with another jet injection device [28].
Although no statistical analysis was performed to com-
pare AEs between the cool.click™ 2 device and needle and
syringe methods of administration of r-hGH, both were
well tolerated in this study in terms of both AEs and local
tolerability and pain assessment. Local redness, generally
mild, was the most commonly observed reaction after
administration of r-hGH by needle and syringe and by
cool.click™ 2. Subjects made no complaints about the
device.
Many factors influence patient adherence to GH therapy,
and are being addressed by needle-free technology,
including the anxiety associated with a 'fear of needles', as
well as occupational needle-related injuries. In addition,
the functionality and appearance of the delivery device are
of key importance for widespread acceptance. The addi-
tional aesthetic and ergonomic benefits incorporated into
the design of cool.click™ 2 mean that it has the potential
to be even more patient-friendly than currently-used
devices.
Conclusion
In conclusion, cool.click™ 2 delivers subcutaneous r-hGH
exposure that is bioequivalent to exposure following
injection by a needle and syringe, but has the additional
advantage of being needle-free, making it particularly suit-
able for children and adults with an aversion to needles.
By increasing patient adherence, cool.click™ 2 should help
to achieve good therapeutic outcomes for GHD and other
disorders that benefit from administration of exogenous
GH.
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